Forus raises $150 million at $3 billion valuation for AI prescription access platform
Forus secures $150M Series C at $3B valuation to scale AI agents automating insurance approvals, financial assistance, and prescription access for U.S.
Forus, the AI healthcare platform formerly known as Tandem, closed a $150 million Series C round at a $3 billion valuation. Bain Capital Ventures led the financing with participation from Thrive Capital, General Catalyst, Accel, Redpoint Ventures, BoxGroup, Pear VC and others. Total capital raised now exceeds $300 million.
Platform capabilities and reach
The system uses specialized AI agents to manage insurance prior authorizations, financial assistance program enrollment, and medication supply coordination. These agents operate inside existing provider workflows rather than as standalone portals. Current coverage includes all 50 U.S. states and patients in 85 percent of residential ZIP codes. The company also maintains partnerships with major biopharma manufacturers that rely on the platform to support patient access programs.
Why administrative automation matters now
Delays between writing a prescription and the patient actually receiving medication remain a persistent source of treatment abandonment and lost revenue for clinics. Manual handling of prior authorizations and assistance applications often requires dedicated staff time that many practices cannot scale. Forus positions its agents as a way to compress those steps while maintaining the accuracy needed to satisfy payer requirements. Early deployments have reported processing time improvements exceeding 30 percent in some workflows.
Practical tradeoffs and what to watch
Success at larger scale will depend on how reliably the agents adapt to the wide variety of payer rules, electronic health record configurations, and state-specific assistance programs. Health systems evaluating the platform will likely focus on measurable reductions in time-to-therapy and on the quality of audit trails the agents produce. The valuation reflects investor confidence that AI can deliver durable efficiency gains in revenue cycle management, yet the ultimate test remains whether those gains hold when the system encounters the long tail of complex cases that still require human judgment.
Sources
Cover photo by Tima Miroshnichenko on Pexels, used under the Pexels License.
Comments (0)
Leave a Comment